MARKET

NVS

NVS

Novartis
NYSE

Real-time Quotes | Nasdaq Last Sale

84.01
+0.51
+0.61%
After Hours: 84.01 0 0.00% 16:47 03/05 EST
OPEN
83.36
PREV CLOSE
83.50
HIGH
84.24
LOW
82.29
VOLUME
2.02M
TURNOVER
--
52 WEEK HIGH
98.52
52 WEEK LOW
69.18
MARKET CAP
189.60B
P/E (TTM)
23.89
1D
5D
1M
3M
1Y
5Y
Global Dry Eye Drugs Market Research Report Manufacturing and Consumption, Outlook and Forecast 2021
Mar 06, 2021 (Heraldkeepers) -- Introspective Market Research Predicts that Dry Eye Drugs Market was valued USD xxxx unit in 2020 and is expected to reach...
Heraldkeepers · 1d ago
Oral Controlled Release Drug Delivery Technology Market In-Depth Analysis on Size, Cost Structure and Prominent Key Players- AstraZeneca Plc., Sun Pharmaceuticals Industries Ltd, Novartis AG, Mylan N.V and Others
Mar 05, 2021 (MARKITWIRED via COMTEX) -- VALLEY COTTAGE, N.Y. - Among all the routes that have been tried and tested for ensuring the accurate and systemic...
Markitwired · 1d ago
Anticonvulsants Market Share, Development by Companies Outlook, Growth Prospects and Key Opportunities by 2026 | Says FMI Analyst
Mar 05, 2021 (MARKITWIRED via COMTEX) -- VALLEY COTTAGE, N.Y. -Impact of COVID-19 on the Healthcare Industry The COVID-19 pandemic has causedsevere impacts...
Markitwired · 1d ago
3 Safe Healthcare Stocks to Ride out the Current Volatility
StockNews.com · 1d ago
Global CAR-T Cell Therapy Market Size, Shares, Trends, Strategies, Impacts, Status, Analysis and Forecast Report 2026
Mar 05, 2021 (Market Insight Reports) -- Selbyville, Delaware, MarketStudyReport.com offers report on Global CAR-T Cell Therapy Market that evaluates...
Market Insight Reports · 1d ago
World Neuroendocrine Tumors (NET) Market Spotlight 2020: Novartis has the Highest Number of Completed Clinical Trials for NETs, with 21 Trials
DUBLIN, March 5, 2021 /PRNewswire via COMTEX/ -- DUBLIN, March 5, 2021 The "Market Spotlight: Neuroendocrine tumors (NET)" report has been added to...
PR Newswire - PRF · 1d ago
Novartis (NVS) & CureVac Collaborate for COVID-19 Vaccine
Novartis (NVS) will manufacture the mRNA and bulk drug product for CureVac's COVID-19 vaccine candidate.
Zacks · 2d ago
Personalized Medicine Is The Next Big Trend For Biotech Stocks & 1 Company Could Radically Disrupt The Industry
Mar 05, 2021 (Penny Stocks via COMTEX) -- Every now and then, a new trend emerges in the stock market that takes investors by surprise in a very profound...
Penny Stocks · 2d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NVS. Analyze the recent business situations of Novartis through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NVS stock price target is 104.67 with a high estimate of 105.00 and a low estimate of 104.00.
EPS
Institutional Holdings
Institutions: 1.63K
Institutional Holdings: 257.36M
% Owned: 11.40%
Shares Outstanding: 2.26B
TypeInstitutionsShares
Increased
368
17.21M
New
198
-1.51M
Decreased
426
13.97M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.51%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Non-Executive Chairman/Independent Director
Joerg Reinhardt
Chief Executive Officer/Executive Board
Vasant Narasimhan
President/Chief Executive Officer
Chris Ilsley
Non-Executive Vice Chairman/Lead Director/Independent Director
Enrico Vanni
Chief Financial Officer/Executive Board
Harry Kirsch
Chief Human Resource Officer/Executive Board
Steven Baert
Corporate Executive/
Michael Ball
Chief Technology Officer/Executive Board
Steffen Lang
Chief Compliance Officer/Chief Risk Officer/Executive Board
Klaus Moosmayer
Executive Board
James Bradner
Executive Board
Shannon Klinger
Executive Board
Richard Saynor
Executive Board
Susanne Schaffert
Executive Board
John Tsai
Executive Board
Marie-France Tschudin
Executive Board
Robert Weltevreden
Secretary
Charlotte Pamer-Wieser
Non-Executive Independent Director
Nancy Andrews
Non-Executive Independent Director
Ton Buechner
Non-Executive Independent Director
Patrice Bula
Non-Executive Independent Director
Srikant Datar
Non-Executive Independent Director
Elizabeth Doherty
Non-Executive Independent Director
Ann Fudge
Non-Executive Independent Director
Bridgette Heller
Non-Executive Independent Director
Simon Moroney
Non-Executive Independent Director
Charles Sawyers
Non-Executive Independent Director
Frans van Houten
Non-Executive Independent Director
Andreas von Planta
Non-Executive Independent Director
William Winters
Declaration Date
Dividend Per Share
Ex-Div Date
01/26/2021
Dividend USD 2.1959459
03/04/2021
01/31/2020
Dividend USD 2.0067876
03/03/2020
--
Dividend USD 1.842184
03/04/2019
--
Dividend USD 1.909
03/06/2018
04/17/2017
Dividend USD 2.303
03/01/2017
04/11/2016
Dividend USD 1.766665
02/24/2016
04/14/2015
Dividend USD 2.259
03/02/2015
05/13/2014
Dividend USD 1.794
02/27/2014
04/01/2013
Dividend USD 2.057
02/26/2013
About NVS
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

Webull offers kinds of Novartis AG (ADR) stock information, including NYSE:NVS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NVS stock methods without spending real money on the virtual paper trading platform.